Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease.

Abstract

We evaluated the efficacy and safety of high-dose intravenous methylprednisolone (1 g x 3 days) pulse therapy followed in the management of acute posterior segment uveitis attacks in 25 patients with Behçet's disease. High-dose intravenous methylprednisolone pulse therapy may be beneficial in the prompt control of severe ocular inflammation and in preventing visual loss.

• Authors: F Nilûfer Yalçindag, Ertugrul Can, Ozden Ozdemir
• Journal: Annals of ophthalmology (Skokie, Ill.) (Ann Ophthalmol (Skokie)) Vol. 39 Issue 3 Pg. 194-7 ( 2007) ISSN: 1558-9951 [Electronic] United States
• PMID: 18025624 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Blood Glucose
• Methylprednisolone

Topics

• Acute Disease
• Adult
• Anti-Inflammatory Agents (administration & dosage, adverse effects, therapeutic use)
• Behcet Syndrome (complications)
• Blood Glucose (metabolism)
• Blood Pressure (drug effects)
• Cataract (chemically induced)
• Female
• Flushing (chemically induced)
• Follow-Up Studies
• Glaucoma (chemically induced)
• Humans
• Male
• Methylprednisolone (administration & dosage, adverse effects, therapeutic use)
• Middle Aged
• Pulse Therapy, Drug
• Retinal Diseases (chemically induced)
• Retrospective Studies
• Treatment Outcome
• Uveitis, Posterior (drug therapy, etiology)
• Weight Gain